Last reviewed · How we verify
Intraosseous Vancomycin
At a glance
| Generic name | Intraosseous Vancomycin |
|---|---|
| Sponsor | Başakşehir Çam & Sakura City Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IO Vancomycin Spine (PHASE2, PHASE3)
- Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trial (PHASE4)
- IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA (NA)
- A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty (PHASE4)
- IO Vancomycin in TSA (PHASE4)
- Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty (PHASE2)
- Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA) (PHASE1, PHASE2)
- Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraosseous Vancomycin CI brief — competitive landscape report
- Intraosseous Vancomycin updates RSS · CI watch RSS
- Başakşehir Çam & Sakura City Hospital portfolio CI